Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy

Journal of Infectious Diseases

Volumn 186, Issue 1, 2002, Pages 23-31

  Wit, Ferdinand W N M ^a   Weverling, Gerrit Jan ^a   Weel, Jan ^a   Jurriaans, Suzanne ^a   Lange, Joep M A ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ALANINE AMINOTRANSFERASE; AMPRENAVIR; ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ; HYDROXYUREA; INDINAVIR; LAMIVUDINE; LIVER ENZYME; LOPINAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CHRONIC HEPATITIS; DRUG FORMULATION; DRUG MEGADOSE; FEMALE; HEPATITIS B; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR;

ADULT; ALANINE TRANSAMINASE; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COHORT STUDIES; FEMALE; HEPATITIS B; HEPATITIS C; HEPATITIS, TOXIC; HIV INFECTIONS; HIV-1; HUMANS; INCIDENCE; LAMIVUDINE; LIVER FUNCTION TESTS; MALE; NEVIRAPINE; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; RISK FACTORS; RITONAVIR; SEX FACTORS; TRANSAMINASES;

EID: 0036642493     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/341084     Document Type: Article

References (38)

1. Adverse effects of antiretroviral therapy
2. Risk factors for hepatotoxicity in HIV-1-infected patients receiving ritonavir and saquinavir with or without stavudine
3. Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection
4. Hepatotoxicity after introduction of highly active antiretroviral therapy
5. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection
6. Hepatitis B or hepatitis C virus infection is a risk factor for severe hepatic cytolysis after initiation of a protease inhibitor-containing antiretroviral regimen in human immunodeficiency virus-infected patients
7. Severe hepatic cytolysis: Incidence and risk factors in patients treated by antiretroviral combinations
8. Adverse effects of reverse transcriptase inhibitors: Mitochondrial toxicity as common pathway
9. Severe hepatic failure related to nevirapine treatment
10. Hypersensitivity syndrome associated with efavirenz therapy
11. Hepatitis C virus-associated hepatitis following treatment of HIV-infected patients with HIV protease inhibitors: An immune restoration disease?
12. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter
13. Delta: A randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals
14. Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: The CAESAR trial
15. Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial
16. Severe hepatitis in three AIDS patients treated with indinavir
17. Severe hepatitis in patients with AIDS and haemophilia B treated with indinavir
18. Acute hepatitis in HIV-infected patients during ritonavir treatment
19. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine
20. A preliminary evaluation of nelfinavir mesylate, an inhibitor of human immunodeficiency virus (HIV)-1 protease, to treat HIV infection
21. Hepatic steatosis and lactic acidosis associated with stavudine treatment in an HIV patient: A case report
22. Outcome and predictors of failure of highly active antiretroviral therapy: One-year follow-up of a cohort of human immunodeficiency virus type 1-infected persons
23. Serious adverse events attributed to nevirapine regimens for postexposure prophylaxis after HIV exposures - Worldwide, 1997-2000
24. Fatal lactic acidosis and liver steatosis associated with didanosine and stavudine treatment: A respiratory chain dysfunction?
25. Lactic acidosis and hepatic steatosis associated with use of stavudine: Report of four cases
26. Adverse effects associated with use of nevirapine in HIV postexposure prophylaxis for 2 health care workers
27. Fatal portal hypertension, liver failure, and mitochondrial dysfunction after HIV-1 nucleoside analogue-induced hepatitis and lactic acidaemia
28. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults
29. Hepatitis B virus infection
30. Hepatitis C
31. Acute exacerbation of chronic hepatitis B virus infection after withdrawal of lamivudine therapy
32. Severe liver toxicity in patients receiving two nucleoside analogues and a non-nucleoside reverse transcriptase inhibitor
33. Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy
34. Severe hepatic and cutaneous adverse effects with nevirapine
35. Liver toxicity caused by nevirapine
36. Incidence of hepatotoxicity and mortality in 21 adult antiretroviral treatment trials
37. Analyses of four key clinical trials to assess the risk of hepatotoxicity with nevirapine: Correlation with CD4 levels, hepatitis B and C seropositivity, and baseline liver functions tests